Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Combined Hormonal Contraception Use & CV Risk

Am J Obstet Gynecol; ePub 2016 Apr 5; Lauring, et al

A high rate of combined hormonal contraceptive use was observed in reproductive age women with a medical contraindication to estrogen use, and these women may be at increased risk for cardiovascular events. This according to study of 987 adult women (46% aged 18 to 25 years) who were mostly white, employed, and married or cohabiting. Researchers found:

• 13% had a medical contraindication to estrogen-containing contraceptive use; migraine with aura (81%) was the most common, followed by hypertension (11%), smokers over age 35 (7%), history of VTE (4%), and diabetes with complications (2%).

• High use of combined hormonal contraceptives was reported among the women with medical contraindications to estrogen at 39%; however, this was not statistically different from women without a medical contraindication (47%).

• Among the women with a contraindication, whether they did or did not use an estrogen-containing contraceptive did not vary by education level, income, or weight.

Citation: Lauring JR, Lehman EB, Deimling TA, Legro RS, Chuang CH. Combined hormonal contraception use in reproductive age women with contraindications to estrogen use. [Published online ahead of print April 5, 2016]. Am J Obstet Gynecol. doi:http://dx.doi.org/10.1016/j.ajog.2016.03.047.